Chardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Chardan Capital issued their FY2024 earnings per share estimates for Dyne Therapeutics in a note issued to investors on Monday, May 6th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings per share of ($2.87) for the year. Chardan Capital currently has a "Buy" rating and a $31.00 target price on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.27) per share.

A number of other brokerages have also recently commented on DYN. Oppenheimer restated an "outperform" rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Monday. Piper Sandler lifted their target price on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. Stifel Nicolaus raised their price objective on Dyne Therapeutics from $35.00 to $41.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Finally, Morgan Stanley began coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an "overweight" rating and a $40.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.75.

Dyne Therapeutics Stock Up 1.0 %

Shares of NASDAQ:DYN traded up $0.26 on Thursday, hitting $25.95. The company had a trading volume of 1,008,521 shares, compared to its average volume of 1,827,590. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $30.27. The firm's 50-day simple moving average is $26.49 and its two-hundred day simple moving average is $18.88. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -6.47 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.17).

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of Dyne Therapeutics by 5.9% during the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company's stock worth $437,000 after purchasing an additional 857 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Dyne Therapeutics during the first quarter worth $28,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Dyne Therapeutics by 5.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company's stock valued at $305,000 after acquiring an additional 1,199 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Dyne Therapeutics by 1.4% in the 1st quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company's stock worth $2,894,000 after purchasing an additional 1,447 shares in the last quarter. Finally, Profund Advisors LLC lifted its stake in Dyne Therapeutics by 9.8% in the 3rd quarter. Profund Advisors LLC now owns 23,793 shares of the company's stock worth $213,000 after purchasing an additional 2,131 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO Joshua T. Brumm sold 5,520 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total transaction of $151,800.00. Following the completion of the sale, the chief executive officer now directly owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Joshua T. Brumm sold 5,520 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $151,800.00. Following the transaction, the chief executive officer now owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Wildon Farwell sold 5,493 shares of the business's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $25.07, for a total transaction of $137,709.51. Following the sale, the insider now owns 163,503 shares of the company's stock, valued at $4,099,020.21. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,875,432 shares of company stock worth $44,368,530. Company insiders own 20.77% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.